From someone who does not post: The constant pe
Post# of 36537
(Total Views: 359)
Posted On: 02/25/2021 2:28:18 PM
From someone who does not post:
The constant peer reviews, over the years, are similar to a book smart person. They go to college on a perpetual basis getting degree after degree, however never get a job when it is all done. This peer review has to happen quickly, so we can move on to get the job!
As far as I'm concerned, what is the value of GNBT/NGIO?
- They have no revenues, even though they bought many companies for $2.50 stock. And these companies HAD revenues that all disappeared.
- They had to borrow money to pay off a judgement in cash (and if they had revenues, they would not have had to borrow).
- They have a valuation appraisal from an accredited firm (although I think it was not the right firm to complete the valuation based on the other companies they value) of $500M+. Well that is only a number on a piece of paper. There is no revenues from NGIO yet. Yes they have received some upfront payments, yet not all the upfront they are expecting. However they is still no revenues until they go thru all 3 phases of trials and get approval to sell. So what value do you put on that? Obviously zero right now because no one is buying the stock up.
Bottom line is the company is stalled right now. Joe stated in the 1/8/2021 PR https://storage.googleapis.com/wzukusers/user...5_2021.pdf " In addition, I will update everyone on our progress and timing on the NuGenerex Immuno-Oncology Nasdaq listing now that our third-party valuation analysis has been completed with a value estimated at over $500 million. This third-party valuation report is the last piece of information required to enable us to set the price per share to meet the standards for the Nasdaq." That is right from their PR. Where is the progress in the last 6 weeks on that " last piece of information required "? NGIO needs to get IPOd NOW and not wait for a peer review. GNBT has no money, the fact they had to borrow money from Oasis at a 16% discount, with an 8% interest yield, 201K free shares as "inducement" as if the 16% discount and 8% interest aren't enough "inducement". Oh, let's tap on the 1.407M warrants exercisable at $0.60. And allow the $1.689M to be converted into stock at $0.60. So if NGIO goes public at $10, then GNBT goes to $6, they make 900% by converting into stock.
This company is bleeding badly AGAIN and our low float of 110M is going to expand significantly unless they go public with NGIO right now. Don't wait. Bring it out at $5 if need be. Let the market determine the risk/reward going forward.
Of course, this is all in my opinion.
A Friend...(movie buffs know that from the movie Disclosure)
The constant peer reviews, over the years, are similar to a book smart person. They go to college on a perpetual basis getting degree after degree, however never get a job when it is all done. This peer review has to happen quickly, so we can move on to get the job!
As far as I'm concerned, what is the value of GNBT/NGIO?
- They have no revenues, even though they bought many companies for $2.50 stock. And these companies HAD revenues that all disappeared.
- They had to borrow money to pay off a judgement in cash (and if they had revenues, they would not have had to borrow).
- They have a valuation appraisal from an accredited firm (although I think it was not the right firm to complete the valuation based on the other companies they value) of $500M+. Well that is only a number on a piece of paper. There is no revenues from NGIO yet. Yes they have received some upfront payments, yet not all the upfront they are expecting. However they is still no revenues until they go thru all 3 phases of trials and get approval to sell. So what value do you put on that? Obviously zero right now because no one is buying the stock up.
Bottom line is the company is stalled right now. Joe stated in the 1/8/2021 PR https://storage.googleapis.com/wzukusers/user...5_2021.pdf " In addition, I will update everyone on our progress and timing on the NuGenerex Immuno-Oncology Nasdaq listing now that our third-party valuation analysis has been completed with a value estimated at over $500 million. This third-party valuation report is the last piece of information required to enable us to set the price per share to meet the standards for the Nasdaq." That is right from their PR. Where is the progress in the last 6 weeks on that " last piece of information required "? NGIO needs to get IPOd NOW and not wait for a peer review. GNBT has no money, the fact they had to borrow money from Oasis at a 16% discount, with an 8% interest yield, 201K free shares as "inducement" as if the 16% discount and 8% interest aren't enough "inducement". Oh, let's tap on the 1.407M warrants exercisable at $0.60. And allow the $1.689M to be converted into stock at $0.60. So if NGIO goes public at $10, then GNBT goes to $6, they make 900% by converting into stock.
This company is bleeding badly AGAIN and our low float of 110M is going to expand significantly unless they go public with NGIO right now. Don't wait. Bring it out at $5 if need be. Let the market determine the risk/reward going forward.
Of course, this is all in my opinion.
A Friend...(movie buffs know that from the movie Disclosure)
(10)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼